| MeSH term | MeSH ID | Detail |
|---|---|---|
| Celiac Disease | D002446 | 16 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Cholelithiasis | D002769 | 16 associated lipids |
| Cholestasis | D002779 | 23 associated lipids |
| Chondrodysplasia Punctata | D002806 | 8 associated lipids |
| Chronic Disease | D002908 | 7 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Coronary Artery Disease | D003324 | 47 associated lipids |
| Coronary Disease | D003327 | 70 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Byars NE and Allison AC | Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. | 1987 | Vaccine | pmid:3499713 |
| Ott G et al. | Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. | 1995 | Vaccine | pmid:8578842 |
| Higgins DA et al. | MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. | 1996 | Vaccine | pmid:8782343 |
| Barnett SW et al. | Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. | 1997 | Vaccine | pmid:9234536 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. | 1994 | Vaccine | pmid:8085385 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. | 1994 | Vaccine | pmid:8085386 |
| Byars NE et al. | Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. | 1994 | Vaccine | pmid:8165851 |
| Heineman TC et al. | A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. | 1999 | Vaccine | pmid:10438046 |
| De Donato S et al. | Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. | 1999 | Vaccine | pmid:10462245 |
| Minutello M et al. | Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. | 1999 | Vaccine | pmid:9987141 |
| Hilgers LA et al. | Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. | 1999 | Vaccine | pmid:9987157 |
| Iorio AM et al. | Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. | 2003 | Vaccine | pmid:12922092 |
| Black S et al. | Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. | 2010 | Vaccine | pmid:20813217 |
| Madhun AS et al. | An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. | 2010 | Vaccine | pmid:21034828 |
| Parretta E et al. | Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. | 2011 | Vaccine | pmid:21406267 |
| Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
| Decaro N et al. | Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. | 2011 | Vaccine | pmid:21272607 |
| Calabro S et al. | Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. | 2011 | Vaccine | pmid:21215831 |
| Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
| Esposito S et al. | Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. | 2011 | Vaccine | pmid:21199699 |
| Esposito S et al. | Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. | 2010 | Vaccine | pmid:20888873 |
| Pellegrini M et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. | 2009 | Vaccine | pmid:19751689 |
| Forrest HL et al. | Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. | 2009 | Vaccine | pmid:19406182 |
| Camilloni B et al. | Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. | 2009 | Vaccine | pmid:19410623 |
| Ansaldi F et al. | Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. | 2010 | Vaccine | pmid:20433807 |
| Tsai T et al. | Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. | 2010 | Vaccine | pmid:19969117 |
| Pietrella D et al. | A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. | 2010 | Vaccine | pmid:20038431 |
| Camilloni B et al. | An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. | 2010 | Vaccine | pmid:20846530 |
| Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
| Della Cioppa G et al. | Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. | 2011 | Vaccine | pmid:21906647 |
| Fox CB et al. | Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | 2011 | Vaccine | pmid:21906648 |
| Radosević K et al. | Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. | 2008 | Vaccine | pmid:18514980 |
| Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
| Puig-Barberà J et al. | Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. | 2007 | Vaccine | pmid:17889411 |
| de Bruijn I et al. | Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. | 2007 | Vaccine | pmid:18063446 |
| Wack A et al. | Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | 2008 | Vaccine | pmid:18162266 |
| Puig-Barberà J et al. | Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. | 2004 | Vaccine | pmid:15530669 |
| O'Hagan DT et al. | Cationic microparticles are a potent delivery system for a HCV DNA vaccine. | 2004 | Vaccine | pmid:15542189 |
| Schultze V et al. | Safety of MF59 adjuvant. | 2008 | Vaccine | pmid:18462843 |
| Iorio AM et al. | Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. | 2012 | Vaccine | pmid:22245606 |
| Hatz C et al. | A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. | 2012 | Vaccine | pmid:22446638 |
| O'Hagan DT et al. | The mechanism of action of MF59 - an innately attractive adjuvant formulation. | 2012 | Vaccine | pmid:22682289 |
| Yu S et al. | Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. | 2012 | Vaccine | pmid:22709954 |
| Chandramouli S et al. | Generation of a parvovirus B19 vaccine candidate. | 2013 | Vaccine | pmid:23827313 |
| Yang WH et al. | Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. | 2013 | Vaccine | pmid:23856331 |
| Tetsutani K and Ishii KJ | Adjuvants in influenza vaccines. | 2012 | Vaccine | pmid:23084848 |
| Nielsen AB et al. | Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. | 2012 | Vaccine | pmid:23036498 |
| Vinay TN et al. | Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). | 2013 | Vaccine | pmid:23896420 |
| Poder A et al. | An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. | 2014 | Vaccine | pmid:24252703 |
| Rouleau I et al. | Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. | 2013 | Vaccine | pmid:24144473 |